Platform technology	HumaMAX®	MucoMAX®
Target disease	CIN1(BLS-H01)	CIN2/3 (BLS-M07)
Stage of disease progress	Normal/HPV infected	HSIL 2)
	LSIL 2)
Treatment mechanism	HumaMAX® Cells infected by the HPV Virus → Prevents virus proliferation byusing BLS-H01 which has an antivirus effect
	MucoMAX® Virus-infected cervical epithelial cells create abnormal cells as time passes,even leading to deformation of the intraepithelial tissues → Disease treatment via inducing immunoreactions

• LSIL : Low-grade squamous intraepithelial lesions
• HSIL: High-grade squamous intraepithelial lesions

Clinical Test

BLS-M07

Outcome

• Since August 2017, Clinical Phase 2b has been in progress with 16 testing agencies
• Goal of clinical tests : To prove the effectiveness of the medicine developed by BL, compared to the above drug
• Currently in a stage to check whether or not there is 75% treatment effectiveness, shown from Phase 1 and 2a, is meaningful from a statistical point of view

Market scale

• The global market estimated to be worth KRW 3.5 trillion, ‘First-in-class’ globally innovative new medicine
• Currently, no treatment options other than "conization" exist for stage 3 cervical cancer and, if a woman becomes pregnant after a conization procedure, the likelihood of side effects such as premature birth and miscarriage as well as recurrences of cancer are high, which makes the development of an effective medicine a pressing issue

Competitiveness

• The best “First-in-its-Class” medicine among a group of similar drugs
• mmunotherapy-based oral intestinal coating capsule : Convenience in administration and reduced psychological burden on the patients in the face of a treatment
• Mechanism to induce mucosal CTL immunity, which is the most ideal means by which to treat cervical mucosal disease : "Inducing antigen-specific immunity" by absorbing antigens into a body through intestinal mucosa with lactic acid bacteria as the transporter

Strategy

• Achieve meaningful effects during Clinical Phase 2b and then proceed with global clinical trials